



7 April 2021

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

European Patent Office issues Notice of Intention to grant NanoCelle® patent

Medlab (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines particularly in the field of oncology, is pleased to advise it has received an *Intention to Grant* notice from the European Patent Office for its patent covering the use of the Company's NanoCelle® sub-micron delivery platform in Europe, including the UK.

The patent EP 16 759 419.3, filed in March 2016 and titled *Transmucosal and transdermal delivery systems*, provides coverage for NanoCelle® in European member states and the UK*, with protection until 2036.

The patent will be the second granted for NanoCelle®, following receipt of an Australian patent (patent number 2016226280) in September 2020. Medlab has also filed patent applications in the US, New Zealand, Singapore, Hong Kong and Canada.

Medlab CEO Dr Sean Hall said, "Receiving Notice of Intent from the European Patent Office represents another important validation of our NanoCelle® drug delivery platform, offering NanoCelle® protection in one of the world's largest markets.

"The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio, it will also support our robust R&D pipeline and commercial partnering focus. We are delighted with this recognition."

NanoCelle® is Medlab's proprietary sub-micron delivery system. NanoCelle® creates nano-sized water-soluble particles that enable optimised delivery of particles, overcoming issues with solubility and degradation. NanoCelle® has potential applications in and out of medicine, including small and large molecule pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. NanoCelle® underpins Medlab's growth strategy by offering near-term partnering opportunities whilst enhancing the Company's pharmaceutical and nutraceutical portfolios.

* The possible countries in which this application may be validated are as follows:

Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino and Turkey. Validation of the patent in Switzerland will automatically extend to Liechtenstein.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab – www.medlab.co

Medlab Clinical is an Australian-based, ASX listed biotech using delivery platforms to enhance medicines, particularly in the field of oncology. In pain management, Medlab is developing cannabis-based medicines. Its lead candidate NanaBis™ equimolar comprising of THC: CBD, is being developed as non-opioid alternative for the treatment of cancer-induced bone pain and has IND approval to enter Phase III clinical trials.

Medlab's proprietary drug delivery platform NanoCelle® is used to enhance a wide range of active ingredients, with commercial opportunities in pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. Medlab's products are proudly validated by research and supported by a growing patent portfolio. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised to deliver more for human health and beyond.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 - sean_hall@medlab.co	Kyahn Williamson, WE Communications T: + 61 0401018828 - kwilliamson@we-worldwide.com
---	--